摘要
多囊卵巢综合征（PCOS）是育龄妇女常见的一类内分泌紊乱疾病，与月经异常、流产以及一系列妊娠相关的并发症有关，同时也是Ⅱ型糖尿病和心血管疾病的高风险人群。在育龄妇女中占5％～10％Ⅲ，在接受辅助生殖助孕治疗的病人中约占50％，但这部分患者接受体外受精（IVF）助孕治疗时，
Objective： To cpmpare the safety and effectiveness between gonadotrophin releasing hormone （GnRH） antagonist protocol after in-vitro maturation （IVM）and long-term protocol after Diane 35 （ethinyloestradiol cyproterone acetate） pretreatment in women with polycystic ovary syndrome （PCOS） receiving in-vitro fertilization （IVF） treatment. Methods： Retrospectively analysing clinical data of 151 PCOS patients receiving IVF treatment in our hospital from 2010 April to 2011 April. The patients were divided into two groups： 49 patients received GnRH antagonist protocol after unsuccessful IVM （ the study group,）, and 102 patients received long-term protocol after one cycle oral Diane 35 pretreatment （the control group）. Basal characteristic of patients and the treatment outcome were compared. Result： The basal LH and the clinical pregnancy rate of study group were significant higher than control group, but the progesterone levels on hCG day, dosage of gonadotrophin, duration of stimulation, overall cost of ovulation induction of study group were significant lower than control group. The cancel rate due to OHSS of study group was lower than control group, and none of the patients in study group occured severe OHSS. Conclusion： The GnRH antagonist protocol after IVM is safer and cost-effective than long-term protocol in PCOS patients.
出处
《生殖医学杂志》
CAS
2012年第2期102-106,共5页
Journal of Reproductive Medicine
关键词
多囊卵巢综合征
卵子体外成熟培养
拮抗剂方案
长方案
Polycystic ovary syndrome
In vitro maturation
Gonadotrophin releasing hormone antagonist
Long protocol
